Published in Virus Weekly, February 9th, 1998
The problem of non-responsiveness to current hepatitis B virus (HBV) vaccines containing recombinant small antigen (r-sAg) from engineered yeast cells is overcome by preS sequences present in the HBV preS2 or middle (preS2-sAg) surface glycoprotein and in the HBV preS1 or large (preS1-preS2-sAg) surface glycoprotein.
Third generation recombinant HBV vaccines including preS sequences are not yet commercially available.
"Several reasons may account for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly